In contrast to the neuroprotective actions of mild glutamatergic synaptic activity,^[@bib1]^ persistent activation of the N-methyl-D-aspartate subtype of glutamate receptors (NMDAR) -- including the extra-synaptic ones^[@bib2]^ -- is known to underlie the pathogenesis of a number of neurological disorders, including Alzheimer\'s disease, amyotrophic lateral sclerosis or stroke.^[@bib3]^ This phenomenon, known as excitotoxicity, causes neuronal apoptotic death through a not yet fully understood mechanism, but it is thought to involve an increase in intracellular Ca^2+^ through NMDAR, followed by plasma membrane depolarization and, hence, opening of voltage-gated Ca^2+^ channels, release from intracellular stores and reversal of the plasma membrane Na^+^/Ca^2+^ exchanger.^[@bib4]^ This process eventually triggers the accumulation of mitochondrial Ca^2+^, leading to increased reactive oxygen species (ROS) formation, mitochondrial energy dysfunction, permeability transition pore opening and cytochrome *c* release.^[@bib5]^ Besides mitochondria, it has also been recently shown that cytoplasmic NADPH oxidase has a key role in ROS production upon NMDAR stimulation.^[@bib6]^ Thus, Ca^2+^ influx activates protein kinase C, which in turn phosphorylates and activates p47^phox^; p47^phox^ coordinates NAPDH oxidase subunit organization, leading to enzyme activation.^[@bib6]^ Regardless the origin of ROS, it is thought that neurons are highly vulnerable to mitochondrial stress, likely because of their inability to sufficiently activate glycolysis and, hence, to transiently compensate energy deficiency.^[@bib7],\ [@bib8]^ In contrast to neurons, astrocytes and other proliferative cells readily invoke glycolysis as a cytoprotective mechanism.^[@bib8],\ [@bib9],\ [@bib10],\ [@bib11]^

Glycolysis is controlled by the activity of 6-phosphofructo-1-kinase, the activity of which is highly dependent on its potent allosteric activator, fructose-2,6-bisphosphate (F2,6P~2~); in the brain, F2,6P~2~ biosynthesis almost exclusively relies on 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) activity.^[@bib12],\ [@bib13]^ Previously, we reported that the inability of neurons to promote cytoprotective glycolysis is because of the virtual absence of PFKFB3.^[@bib14]^ Furthermore, we recently found that PFKFB3, through its KEN motif, is a substrate of the E3 ubiquitin ligase, anaphase-promoting complex (APC)-Cdh1 (APC^Cdh1^),^[@bib15]^ which accounts for the high instability of PFKFB3 and low glycolytic rate in neurons.^[@bib15]^

Inhibition of APC^Cdh1^ in postmitotic neurons triggers an accumulation of its substrate, cyclin B1, which mediates apoptotic death.^[@bib16]^ Moreover, cyclin B1 accumulation can also be recapitulated by NMDAR stimulation, which activates cyclin-dependent kinase 5 (Cdk5)-mediated Cdh1 phosphorylation, leading to APC^Cdh1^ inhibition.^[@bib17]^ In view of the control that APC^Cdh1^ exerts over PFKFB3 stability,^[@bib15]^ here we hypothesized whether NMDAR stimulation, *via* APC^Cdh1^ inhibition,^[@bib17]^ regulates PFKFB3 protein levels in neurons. We show that NMDAR activation, through inhibition of APC^Cdh1^ caused PFKFB3 stabilization leading to increased glycolysis and reduced activity of the pentose-phosphate pathway (PPP). This metabolic alteration triggered oxidative damage and excitotoxic neuronal death, thus suggesting that modulators of neuronal energy metabolism should be considered as targets in therapeutic strategies against neurodegenerative diseases.

Results
=======

In order to test whether rat primary cortical neurons in culture responded to glutamate receptor activation, we first monitorized the changes in Fura-2 fluorescence. As shown in [Figure 1a](#fig1){ref-type="fig"}, Fura-2 F335/F363 ratio -- an index of intracellular Ca^2+^ levels -- increased by ∼1.3-fold immediately after the addition of glutamate (100 *μ*M) or N-methyl-D-aspartate (NMDA; 100 *μ*M). Furthermore, pre-incubation of neurons with the NMDAR antagonist, MK801 (10 *μ*M), prevented by ∼60% glutamate-mediated increase in F335/F363 ratio ([Figure 1a](#fig1){ref-type="fig"}, left panel); MK801 almost abolished (by ∼90%) NMDA-mediated increase in F335/F363 ratio ([Figure 1a](#fig1){ref-type="fig"}, right panel). These results suggest that, under our experimental conditions -- cells grown in serum-based medium -- cortical neurons express functional NMDAR and, hence, are useful for the study of excitotoxic-mediated metabolic changes. To investigate whether glutamate receptor activation controls PFKFB3 stability, we then incubated neurons with glutamate (100 *μ*M/15 min), and the levels of PFKFB3 protein were analyzed by western blotting. As shown in [Figure 1b](#fig1){ref-type="fig"}, glutamate triggered a time-dependent increase in PFKFB3, an effect that was maximal (by ∼2.1-fold) after 6 h. To see whether this effect was mediated by NMDAR, neurons were incubated with NMDA (100 *μ*M/15 min), and PFKFB3 protein levels analyzed 6 h later. As depicted in [Figure 1c](#fig1){ref-type="fig"}, NMDA mimicked glutamate at increasing PFKFB3. Moreover, incubation of neurons with MK801 prevented glutamate-mediated increase in PFKFB3 ([Figure 1d](#fig1){ref-type="fig"}). Glutamate did not alter PFKFB3 mRNA levels ([Figure 1e](#fig1){ref-type="fig"}). These results suggest that activation of NMDAR stabilizes PFKFB3 protein in neurons.

Next, we investigated the involvement of APC^Cdh1^ activity in determining PFKFB3 stabilization by NMDAR. In view that NMDAR activation promotes APC^Cdh1^ inhibition by Cdk5-mediated phosphorylation of Cdh1,^[@bib17]^ we tested whether this observation could be confirmed in our conditions. As shown in [Figure 2a](#fig2){ref-type="fig"}, glutamate (100 *μ*M/15 min) promoted, after 4 h, H1 phosphorylation in neuronal samples immunoprecipitated with anti-Cdk5; furthermore, this effect was prevented by MK801, suggesting NMDAR-mediated activation of Cdk5 activity. In addition, Cdh1 was phosphorylated -- suggesting APC^Cdh1^ inhibition -- 6 h after glutamate treatment, an effect that was also prevented by MK801 ([Figure 2b](#fig2){ref-type="fig"}). To further investigate if APC^Cdh1^ activity regulated PFKFB3 stability upon glutamate receptor stimulation, neurons were transfected with a green fluorescent protein (GFP)-PFKFB3 construct to visualize PFKFB3 subcellular localization by confocal microscopy. PFKFB3 was mainly localized in the nucleus of neurons, but glutamate treatment promoted its accumulation, as revealed by the spread (nuclear plus cytosolic) localization ([Figures 2c and d](#fig2){ref-type="fig"}). Interestingly, Cdh1 overexpression prevented this effect, suggesting that deficiency in active Cdh1 was responsible for glutamate-mediated PFKFB3 spreading ([Figures 2c and d](#fig2){ref-type="fig"}). Furthermore, expression of a GFP-PFKFB3 form with its KEN box mutated to AAA (mut-PFKFB3), hence, insensitive to APC^Cdh1^ activity,^[@bib15]^ showed the spread-like localization, regardless of glutamate treatment ([Figures 2c and d](#fig2){ref-type="fig"}). Thus, glutamate-mediated PFKFB3 stabilization occurs via APC^Cdh1^ inhibition.

To elucidate whether NMDAR-mediated PFKFB3 protein stabilization had functional consequences for neuronal metabolism, we assessed the rates of glycolysis and PPP, as well as the glutathione redox status. The efficacy of a small interfering RNA against PFKFB3 (siPFKFB3) to prevent PFKFB3 protein accumulation was first tested. To do so, primary neurons were transfected with the GFP-PFKFB3 complementary DNA (cDNA) construct, and PFKFB3 protein was determined using an anti-flag (anti-GFP) antibody. As shown in [Figure 3a](#fig3){ref-type="fig"}, PFKFB3 was accumulated 6 h after glutamate (100 *μ*M/15 min) incubation in control neurons (siControl); however, transfection of neurons with an siPFKFB3 decreased PFKFB3 protein abundance in control neurons and prevented glutamate-mediated PFKFB3 accumulation. We then assessed the rate of glycolysis, and we found it to be significantly enhanced, after 6 h, by glutamate treatment ([Figure 3b](#fig3){ref-type="fig"}); moreover, this was abolished by preventing PFKFB3 accumulation using the siPFKFB3 ([Figure 3b](#fig3){ref-type="fig"}). In view that glycolysis and PPP are two interconnected metabolic pathways, we then assessed whether the increase in glycolysis altered glucose utilization through the PPP. We found that glutamate treatment decreased, after 6 h, the rate of PPP, an effect that was abolished by siPFKFB3 ([Figure 3c](#fig3){ref-type="fig"}). Thus, glutamate triggers a PFKFB3-dependent increase in glycolysis and decrease in the PPP.

It has been previously shown that glucose metabolism through the PPP is neuroprotective^[@bib15],\ [@bib18],\ [@bib19]^ because of its NADPH-regenerating function. Thus, NADPH is an essential cofactor for glutathione regeneration, hence, the PPP becomes necessary to prevent neuronal death by oxidative stress.^[@bib18]^ Thus, we next aimed to elucidate whether the metabolic PPP/glycolytic shift triggered by glutamate treatment induced oxidative stress. As shown in [Figure 3d](#fig3){ref-type="fig"}, total glutathione (GSx) was unaltered, but its oxidized form (GSSG) and the glutathione oxidized status (GSSG/GSx ratio) significantly increased 6 h after glutamate treatment, and these effects were prevented by siPFKFB3. To further support evidence for oxidative stress, we next evaluated whether a putative increased ROS production by glutamate could be rescued by either knocking down a key glycolytic enzyme, phosphoglucose isomerase (PGI), or by overexpressing glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the PPP that we have previously shown to be efficient in neurons.^[@bib15],\ [@bib18]^ The efficacy of these tools were first tested by western blotting ([Figure 4a](#fig4){ref-type="fig"}); thus, transfection of neurons with the siRNA against PGI efficiently knocked down PGI protein, whereas overexpression of the cDNA encoding G6PD increased neuronal G6PD abundance. Glutamate treatment (100 *μ*M/15 min) increased, after 6 h, neuronal ROS, an effect that was prevented by knocking down PGI or PFKFB3, as it was by overexpressing G6PD, or by blocking NMDAR with MK801 ([Figure 4b](#fig4){ref-type="fig"}). To assess neuronal vulnerability to oxidative stress in this paradigm, we then analyzed the proportion of annexin V^+^/7AAD^−^ neurons (indicating neurons that had been targeted to apoptosis) after glutamate treatment. We found that glutamate increased, though modestly, apoptotic neuronal death via a mechanism that could be prevented by silencing PGI or PFKFB3, as well as by overexpressing G6PD or blocking NMDAR ([Figure 4c](#fig4){ref-type="fig"}). Together, these results indicate that NMDAR activation triggers oxidative stress and targets neurons for apoptotic death by shifting PPP to glycolysis.

Finally, we sought to elucidate whether APC^Cdh1^ activity was responsible for PFKFB3-mediated oxidative stress and neurodegeneration in excitotoxicity. As shown in [Figure 5a](#fig5){ref-type="fig"}, glutamate increased ROS in neurons transfected with low levels of wild-type PFKFB3 cDNA. However, transfection of neurons with identical cDNA amounts of the KEN box-mutant form of PFKFB3 (mut-PFKFB3) increased ROS to levels similar to those triggered by glutamate; moreover, glutamate did not further enhance ROS in neurons expressing mut-PFKFB3 ([Figure 5a](#fig5){ref-type="fig"}). Interestingly, apoptotic death triggered by glutamate in neurons transfected with PFKFB3 was mimicked by mut-PFKFB3 ([Figure 5b](#fig5){ref-type="fig"}). Thus, expression of APC^Cdh1^-insensitive PFKFB3 mimics glutamate at causing oxidative stress and neuronal death.

Discussion
==========

Neurons continuously degrade the glycolytic-promoting enzyme PFKFB3 by APC^Cdh1^ activity, and this allows a considerable proportion of glucose to be oxidized via the PPP, which functions as an antioxidant and survival metabolic pathway.^[@bib15]^ Here, we show that a short-term activation of glutamate receptors in cortical neurons triggers delayed, time-dependent PFKFB3 protein accumulation; the lack of change in the PFKFB3 mRNA abundance ruled out a transcriptional effect. Moreover, NMDA mimicked glutamate, and NMDAR antagonist MK801 prevented PFKFB3 accumulation, indicating the direct involvement of NMDAR stimulation in PFKFB3 stabilization. Previously, it was reported that NMDAR stimulation in cortical neurons promotes, in a Ca^2+^-dependent manner, p35 cleavage to p25 by calpain leading to Cdk5 activation.^[@bib20]^ Here, we show that, under our experimental culture conditions, rat primary cortical neurons efficiently responded to NMDAR stimulation, as judged by the MK801-inhibitable increased intracellular Ca^2+^ levels. Moreover, we show that glutamate induced Cdk5 activation in a process that was antagonized by MK801, indicating the involvement of NMDAR. Given that NMDAR-mediated activation of Cdk5 phosphorylates Cdh1 leading to APC^Cdh1^ inhibition,^[@bib17]^ we hypothesized that the stabilization of PFKFB3 could be consequence of NMDAR-mediated APC^Cdh1^ inhibition. In good agreement with the presence of a nuclear-targeting motif in PFKFB3,^[@bib21]^ we found that expressed PFKFB3 was localized in the nucleus, where neurons actively degraded it. In addition, we show that Cdh1 was phosphorylated by glutamate treatment, and that this was accompanied by cellular spread of PFKFB3 from the nucleus to cytosol in a Cdh1-inhibitable process; interestingly, the PFKFB3 mutant form lacking the Cdh1-recognizing KEN motif spontaneously accumulated. Together, these results indicate that PFKFB3 nuclear stabilization followed by cytosolic spread is the consequence of APC^Cdh1^ inhibition. The mechanism whereby PFKFB3 is released from the nucleus remains unclear, although the physiological significance is likely in view of the cytoplasmic localization of the PFKFB3 target, 6-phosphofructo-1-kinase.

NMDAR-mediated PFKFB3 protein stabilization led to increased PFKFB3 activity and efficiently upregulated the rate of glycolysis in neurons. In previous studies, neurons failed to upregulate glycolysis immediately after the bioenergetic stress caused by mitochondrial inhibitors^[@bib8],\ [@bib22]^ or NMDAR activation.^[@bib14]^ However, it should be noted that PFKFB3 stabilization takes place several hours after glutamate treatment, thus explaining the absence of measurable short-term glycolytic stimulation in cortical neurons in the previous studies.^[@bib8],\ [@bib14],\ [@bib22]^ Accordingly, the delayed increase in glycolysis that we observe does not appear to be a neuronal attempt to rapidly compensate for the mitochondrial energy dysfunction, which occurs immediately after NMDAR stimulation.^[@bib7]^ Instead, the delayed glycolysis activation reflects a long-term metabolic adaptation of neurons by excitotoxic insult; however, such an adaptation concurs with concomitant decrease in the rate of glucose oxidation through the PPP, hence, triggering oxidative stress and neurotoxicity. Intriguingly, although the stimulation of glycolysis is cytotoxic in neurons, it is cytoprotective in astrocytes.^[@bib8]^ This different outcome shown by neurons and astrocytes is consistent with the expression of a robust antioxidant system in astrocytes that is not present in neurons.^[@bib23]^ Upon inhibition of mitochondrial respiration, astrocytes switch on glycolysis, via the 5′-AMP-activated protein kinase-PFKFB3 pathway,^[@bib14]^ to compensate for the ATP deficiency without affecting their antioxidant status.^[@bib24]^ However, shifting glucose utilization from PPP to glycolysis in neurons compromises the efficacy of the critical antioxidant NADPH-glutathione regenerating system, hence causing delayed neurotoxicity. Importantly, both the increase in glycolysis and the decrease in PPP could be fully abolished by siPFKFB3, indicating that both metabolic pathways are wholly controlled by PFKFB3. In this context, it should be mentioned that Tp53-inducible glycolysis and apoptosis regulator (TIGAR), by catalyzing F2,6P~2~ degradation inhibits glycolysis and stimulates PPP.^[@bib25]^ Thus, the control over F2,6P~2~ concentrations by either PFKFB3 -- with a main fructose-6-phosphate-2-kinase activity^[@bib12],\ [@bib13]^ -- or TIGAR -- with fructose-2,6-bisphosphatase activity^[@bib25]^ -- appears to determine the fate of glucose metabolism. However, no evidence for NMDAR-mediated p53 upregulation is currently available, hence, remaining elusive whether TIGAR induction has a determinant role in neuronal metabolic change upon NMDAR stimulation.

The metabolic PPP to glycolysis shift triggered by NMDAR stimulation was accompanied by oxidative stress, as revealed both by an increase in the oxidized glutathione redox status and by the increased mitochondrial ROS, as well as apoptotic neuronal death. These data contrast with those reporting that NMDAR-mediated increase in neuronal ROS could be blocked with 6-aminonicotinamide, an inhibitor of PPP that produces NADPH required for NADPH oxidase activity.^[@bib6]^ Whether the different neuronal settings (defined *versus* serum-based media) or the types of tools used (pharmacological *versus* genetic approaches to modulate glycolysis and PPP) are responsible for this apparent controversy remains elusive. However, in our hands, silencing PFKFB3 or PGI, which effectively inhibited glycolysis,^[@bib15]^ or G6PD overexpression, a potent activator of the PPP,^[@bib18]^ prevented such a metabolic switch and the concomitant ROS production by NMDAR stimulation. In fact, PPP activity produces reduced equivalents in the form of NADPH,^[@bib26]^ which is also a necessary cofactor for antioxidant glutathione regeneration.^[@bib18]^ Thus, PFKFB3 silencing significantly prevented the increase in oxidized glutathione status caused by NMDAR stimulation and this was critical at determining neuronal survival. Interestingly, it has been shown that, when oxidized, cytochrome *c* is released from mitochondria, hence promoting apoptotic neuronal death, and that PPP activity is essential at maintaining cytochrome *c* reduced.^[@bib27]^ Our results, showing oxidative stress and neurodegeneration following PFKFB3 stabilization by NMDAR stimulation, confirm the critical role of PPP at regulating neuronal apoptosis. Furthermore, they show that the loss of PPP activity by APC^Cdh1^ inhibition is a novel and important player in excitotoxicity. Together, these findings highlight the importance of metabolic modulation in excitotoxicity and neurodegeneration and emphasize that metabolic targets should be considered when designing therapeutic strategies.

Materials and Methods
=====================

Plasmid constructions and site-directed mutagenesis
---------------------------------------------------

The rat PFKFB3 full-length cDNA (splice variant K6; 1563 bp; accession number BAA21754) was obtained, by reverse-transcriptase polymerase chain reaction (RT-PCR), at our laboratory.^[@bib15]^ PFKFB3 cDNA was fused, at its 5′-terminus, with the full-length cDNA encoding the GFP and subcloned in pCDNA3.0 vector. This GFP-PFKFB3 cDNA fusion construct was then subjected to site-directed mutagenesis of its KEN-box to AAA using the QuikChange XL site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) using the following forward and reverse primers, respectively: 5′-ATCCTTCATTTTGCC[GC]{.ul}A[GC]{.ul}A[GC]{.ul}TGACTTCAAGGC-3′ and 5′-ATGCCTTGAAGTCA[GC]{.ul}T[GC]{.ul}T[GC]{.ul}GGCAAAATGAAGG-3′ (mutated nucleotides underlined). Human full-length Cdh1 cDNA (accession number NM_016263) was a generous gift of Dr. J Pines (Gurdon Institute, University of Cambridge, UK).

RNA interference
----------------

To knockdown PGI (accession number NM_207192), we used the following sequence for siRNA: 5′-CCTTACCAGACGTAGTGTT-3′ (nt 1248--1266). To knockdown PFKFB3 we used the sequence 5′-AAAGCCTCGCATCAACAGC-3′ (nt 1908--1926). Both siRNAs were previously validated at our laboratory for efficacy.^[@bib14],\ [@bib15]^ An siRNA against luciferase (5′-CTGACGCGGAATACTTCGATT-3′) was used as control.

RT-PCR analysis
---------------

Total RNA was purified from neurons using a commercially available kit (Sigma, Saint Louis, MO, USA). PFKFB3 mRNA expression was analyzed by 4.5% agarose electrophoresis after RT-PCR using the following forward and reverse oligonucleotides, respectively: 5′-CCAGCCTCTTGACCCTGATAAATG-3′ and 5′-TCCACACGCGGAGGTCCTTCAGAT-3′ for PFKFB3, and 5′-CTGGCGTCTTCACCACCAT-3′ and 5′-AGGGGCCATCCACAGTCTT-3′ for GAPDH. Reverse transcription was performed at 48 °C for 50 min, and PCR conditions were 10 min at 95 °C, 35 cycles of 1 min at 95 °C, 1 min at 58 °C and 30 s at 68 °C. Final extension was carried out for 10 min at 72 °C. In no case was a band detected by PCR without reverse transcription.

Antibodies
----------

An anti-PFKFB3 (K3-K6 splice variants) antibody was generated, by rabbit immunization with the synthetic peptide ^508^MRSPRSGAESSQKH^521^-C, at our laboratory as previously described.^[@bib15]^ A commercial anti-PFKFB3 antibody raised against a C-terminal region of the human PFKFB3 (protein accession Q16875; catalog number H00005209-M08, Novus Biologicals, Cambridge, UK) was also used; this antibody cross-reacts with human and rat PFKFB3, thus recognizing a region that is shared by all translational products of the rat K1 to K8 PFKFB3 mRNA splice variants. Anti-Cdh1 (AR38) was a generous gift from J Gannon (Clare Hall Laboratories, Cancer Research, UK). Anti-Cdk5 (C-8) and anti-PGI (K-16) were from Santa Cruz Biotechnology (Heidelberg, Germany). Anti-GFP was purchased from Abcam (Cambridge Science Park, Cambridge, UK). Anti-G6PD and anti-GAPDH were purchased from Sigma, and anti-phosphoserine from Zymed (Invitrogen, Groningen, The Netherlands).

Cell cultures
-------------

Cortical neurons in primary culture were prepared from fetal (E16) Wistar rats. Cells were seeded (2.5 × 10^5^ cells/cm^2^) in DMEM (Sigma) supplemented with 10% (v/v) fetal calf serum (Roche Diagnostics, Heidelberg, Germany) and incubated at 37 °C in a humidified 5% CO~2~-containing atmosphere. After 48 h of plating, the medium was replaced with DMEM supplemented with 5% horse serum (Sigma) and with 20 mM D-glucose. On day 4, cytosine arabinoside (10 *μ*M) was added in order to prevent non-neuronal proliferation. Cells were used by day 6, when enrichment was ∼99% (neurofilament; data not shown).

Cell treatments
---------------

Transfection of cells with plasmid vectors was carried out using 0.16--1.6 *μ*g/ml of the plasmids, as indicated in the figure legends. All transfections were performed using lipofectamine 2000 (Invitrogen) following the manufacturer\'s instructions, at day 5 *in vitro*. After 6 h, the medium was removed and cells were further incubated overnight in the presence of culture medium. For RNA interference experiments, siRNAs (purchased from Thermo Fisher Scientific, Lafayette, CO, USA; sequences described above) were used. In dose-response preliminary settings, primary neurons were transfected, using Lipofectamine 2000 with 20--100 nM of the siRNAs, which showed a dose-dependent effect; only the results using 100 nM are shown. siRNA transfections were performed at day 3 *in vitro* and experiments were performed at day 6, when an efficient knockdown of the target proteins was obtained. For NMDAR activation, neurons at 6 days *in vitro* were incubated with 100 *μ*M glutamate (plus 10 *μ*M glycine) or 100 *μ*M NMDA (plus 10 *μ*M glycine) in buffered Hanks\' solution (pH 7.4) for 15 min.^[@bib7]^ When indicated, incubations were performed in the presence of MK-801 (10 *μ*M; Sigma). Neurons were then washed and further incubated in culture medium for the indicated time period.

Flow cytometric analysis of apoptotic cell death
------------------------------------------------

APC/C-conjugated annexin-V and 7-aminoactinomycin D (7-AAD) (Becton Dickinson Biosciences, San Jose, CA, USA) were used to determine quantitatively the percentage of apoptotic neurons by flow cytometry. Cells were stained with annexin V-APC and 7-AAD, following the manufacturer\'s instructions, and were analyzed on a FACScalibur flow cytometer (15 mW argon ion laser tuned at 488 nm) using the CellQuest software software (BDB). Both GFP^+^ and GFP^−^ cells were analyzed separately and the annexin V-APC-stained cells that were 7-AAD-negative were considered to be apoptotic.^[@bib15]^

Detection of ROS
----------------

This was carried out using MitoSox-Red (Invitrogen). Neurons were incubated with 2 *μ*M MitoSox-Red for 30 min, washed with PBS and the fluorescence assessed by flow cytometry.^[@bib15]^

Measurement of the glycolytic and PPP fluxes
--------------------------------------------

Suspensions of known amounts of cells (4--5 × 10^5^ cells) obtained by smooth detaching from the cultures 6 h after glutamate treatments, were incubated in sealed vials containing a central well, which was used for ^14^CO~2~ or ^3^H~2~O trapping. Cells were incubated in the presence of 1 *μ*Ci of either D-\[1-^14^C\] glucose or D-\[6-^14^C\] glucose for PPP determinations, whereas 5 *μ*Ci of D-\[3-^3^H\] glucose were used for glycolytic flux determinations, both in a Krebs--Henseleit buffer (11 mM Na~2~HPO~4~, 122 mM NaCl, 3.1 mM KCl, 0.4 mM KH~2~PO~4~, 1.2 mM MgSO~4~, 1.3 mM CaCl~2~; pH 7.4) containing 5 mM D-glucose at 37 °C. In order to ensure an adequate O~2~ supply for oxidative metabolism by the cells throughout the 90 min incubation period, the gas phase in the vials containing the cells was supplied with extra O~2~ before the vials were sealed. The glycolytic flux was measured by assaying the rate of ^3^H~2~O production from \[3-^3^H\]glucose, as detailed previously.^[@bib15]^ The PPP flux was measured by assessing the difference between ^14^CO~2~ production from \[1-^14^C\]glucose -- which decarboxylates via the 6-phosphogluconate dehydrogenase-catalyzed reaction -- and that of \[6-^14^C\]glucose -- which decarboxylates via the tricarboxylic acid cycle.^[@bib18],\ [@bib28]^

Glutathione measurements
------------------------

For glutathione determinations, neurons were treated with 1% (w/v) sulfosalicylic acid and centrifuged at 13 000 × *g* for 5 min at 4 °C. GSx (the amount of reduced glutathione (GSH), plus two times the amount of oxidized glutathione (GSSG)) and GSSG concentrations were measured in the supernatants using the enzymatic method of Tietze.^[@bib29]^ GSSG was quantified after derivatization of GSH in the samples with 2-vinylpyridine. Data were extrapolated to those obtained with GSSG standards (0--5 *μ*M for GSSG; 0--50 *μ*M for GSx). The glutathione redox status was expressed as the GSSG/GSx ratio, as previously described.^[@bib18],\ [@bib30]^

Fura-2 fluorescence measurements
--------------------------------

To estimate the intracellular Ca^2+^-dependent changes by NMDAR stimulation in cortical neurons we used the fluorescent probe Fura-2 (acetoxymethyl-derivative; Life Technologies, Eugene, OR, USA), as previously described.^[@bib31]^ Essentially, neurons at 6 days *in vitro*, seeded in 96-well plates (Nunc), were incubated with Fura-2 (2 *μ*M; dissolved in dimethyl sulphoxide (DMSO)) for 40 min in DMEM at 37 °C. Then, cells were washed and further incubated with standard buffer (140 mM NaCl, 2.5 mM KCl, 15 mM Tris-HCl, 5 mM D-glucose, 1.2 mM Na~2~HPO~4~, 1 mM MgSO~4~ and 1 mM CaCl~2~, pH 7.4) for 30 min and 37 °C. Finally, the standard buffer was removed and experimental buffer (140 mM NaCl, 2.5 mM KCl, 15 mM Tris-HCl, D-glucose, 1.2 mM Na~2~HPO~4~, and 2 mM CaCl~2~, pH 7.4), either in the absence or in the presence of MK801 (10 *μ*M), was added. Emissions at 510 nm, after excitations at 335 and 363 nm, respectively, were recorded at 1 s intervals in a Varioskan Flash (Thermo Fischer, Vantaa, Finland) spectrofluorometer at 32 °C. After ∼10 s, glutamate (100 *μ*M) or NMDA (100 *μ*M) (plus 10 *μ*M glycine) was injected and emissions were further recorded for 50 s. Ca^2+^-dependent fluorescence changes were estimated by representing the ratio of fluorescence emitted at 510 nm obtained after excitation at 335 nm divided by that at 363 nm (F335/F363). Background subtraction was accomplished from emission values obtained in Fura-2-lacking (DMSO-containing) neurons. In preliminary experiments, the Ca^2+^ specificity of the measurements was tested in Ca^2+^-free experimental buffer containing 1 mM ethylene glycol tetraacetic acid (EGTA), which fully prevented the changes in 510 nm emissions (data not shown). At least, six wells were recorded per condition in each experiment (*n*=4 experiments) and the averaged values are shown.

Western blot analysis
---------------------

After transfections and treatments, neurons were lysed in RIPA buffer (2% sodium dodecylsulphate, 2 mM ethylene diamine tetraacetic acid (EDTA), 2 mM EGTA, 50 mM Tris; pH 7.5), supplemented with phosphatase inhibitors (1 mM Na~3~VO~4~, 50 mM NaF) and protease inhibitors (100 *μ*M phenylmethylsulfonyl fluoride, 50 *μ*g/ml anti-papain, 50 *μ*g/ml pepstatin, 50 *μ*g/ml amastatin, 50 *μ*g/ml leupeptin, 50 *μ*g/ml bestatin and 50 *μ*g/ml soybean trypsin inhibitor) and boiled for 5 min. Aliquots of cell extracts were subjected to sodium dodecyl sulfate (SDS) polyacrylamide gel (MiniProtean, Bio-Rad, Hercules, CA, USA) and blotted with antibodies overnight at 4 °C. Signal detection was performed with an enhanced chemiluminescence kit (Pierce, Thermo Scientific, Waltham, MA, USA).

Immunoprecipitation and Cdk5 kinase activity
--------------------------------------------

Neurons were lysed in ice-cold buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10 mM EDTA, 2 mM EGTA, 1% NP-40, supplemented with the phosphatase and protease inhibitors cited above. Cell extracts were clarified by centrifugation and supernatants (50 *μ*g of protein for immunoprecipitation experiments, 500 *μ*g for Cdk5 kinase assays) were incubated with anti-Cdh1 or anti-Cdk5, overnight at 4 °C, followed by the addition of 15--30 *μ*l of protein A-sepharose (GE Healthcare Life Sciences, Uppsala, Sweden) for 1--2 h at 4 °C. Immunoprecipitates were extensively washed with lysis buffer and either detected by western blot analysis against anti-phosphoserine or resuspended in kinase buffer (20 mM Tris-HCl pH 7.6, 20 mM MgCl~2~, 2 mM MnCl~2~, 1 mM EDTA, 1 mM EGTA, 0.1 mM dithiothreitol) containing 20 *μ*M ATP, 10 *μ*Ci of \[*γ*-^32^P\]ATP and histone-H1 (50 *μ*g/ml; Sigma) for SDS-polyacrylamide gel (12%) electrophoresis; transferred proteins were visualized by autoradiography and anti-Cdk5 blotting.^[@bib32]^

Protein determinations
----------------------

Protein concentrations were determined in the cell suspensions, lysates or in parallel cell culture incubations after solubilization with 0.1 M NaOH. Protein concentrations were determined as described^[@bib33]^ using bovine serum albumin as a standard.

Confocal microscopy
-------------------

Neurons were grown on glass coverslips. After transfections and treatments they were fixed with 4% (v/v in PBS) paraformaldehyde for 20 min and incubated with DAPI (30 *μ*M; Sigma). Confocal microscopy images were obtained with a Leica SP5 microscope (DMI-6000B model; Leica Microsystems GmbH, Wetzlar, Germany).

Statistical analysis
--------------------

Measurements from individual cultures were always carried out in triplicate. The results are expressed as mean±S.E.M. values for three different culture preparations. Statistical analysis of the results was performed by one-way analysis of variance (ANOVA), followed by the least significant difference multiple range test. In all cases, *P*\<0.05 was considered significant.
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:   N-methyl-D-aspartic acid

NMDAR

:   N-methyl-D-aspartic acid receptor

PFKFB3

:   6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3
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TIGAR
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![Activation of NMDAR stabilizes PFKFB3 protein in neurons. (**a**) Incubation of rat primary cortical neurons with glutamate (left panel) or NMDA (right panel) increased the ratio of Fura-2-dependent fluorescence (at 510 nm) obtained after excitation at 335/363 nm (F335/F363), indicating an increase in intracellular Ca^2+^. MK801 (10 *μ*M) partially prevented glutamate-induced changes in F335/F363 ratio and most of NMDA-dependent F335/F363 ratio changes. (**b**) Incubation of neurons with glutamate (100 *μ*M/15 min) triggered time-dependent increase in PFKFB3 protein, which was maximal after 6 h. (**c**) NMDA (100 *μ*M/15 min) mimicked glutamate at increasing PFKFB3. (**d**) NMDA receptor antagonist, MK801 (10 *μ*M), prevented glutamate-mediated increase in PFKFB3. (**e**) Glutamate (100 *μ*M/15 min) did not change PFKFB3 mRNA levels, as revealed by the unaltered intensity of the predicted 300 bp band after reverse-transcription of total RNA samples, followed by polymerase chain reaction (RT-PCR) using specific oligonucleotides for PFKFB3; GAPDH (279 bp band) was used as loading control; the black/white inverted images of the agarose gels are shown; w/o RT, RT-PCR for PFKFB3 without reverse transcriptase](cdd201233f1){#fig1}

![Glutamate-mediated PFKFB3 stabilization occurs *via* Cdk5-mediated inhibition of APC^Cdh1^ activity. (**a**) Glutamate treatment (100 *μ*M/15 min) increased, after 1 h, Cdk5-mediated H1 phosphorylation in rat primary cortical neurons; this effect was fully abolished by MK801 (10 *μ*M). (**b**) Cdh1 is phosphorylated 6 h after glutamate treatment (100 *μ*M/15 min), an effect that was prevented by MK801 (10 *μ*M). (**c**) Confocal microscopy images of neurons transfected with GFP-PFKFB3 reveals its nuclear localization. Glutamate promotes PFKFB3 accumulation, as revealed by its spread (nuclear plus cytosolic) localization; Cdh1 overexpression prevented this effect. GFP-PFKFB3 mutated on its KEN box (KEN → AAA; mut-PFKFB3) showed the spread-like localization, regardless of glutamate treatment. (**d**) Percentage of neurons showing nuclear or spread GFP-PFKFB3 localization in the experiments shown in **c**; these data were obtained by analyzing ∼30 neurons per condition per neuronal preparation (*n*=4). ^\*^*P*\<0.05 *versus* the corresponding (nuclear or cytoplasmic) PFKFB3-none condition (ANOVA)](cdd201233f2){#fig2}

![Glutamate stimulates PFKFB3-dependent increase in glycolysis, a decrease in PPP and promotes glutathione oxidation in neurons. (**a**) Incubation of GFP-PFKFB3-expressing neurons with glutamate (100 *μ*M/15 min) induced, 6 h after treatment, PFKFB3 accumulation in control, siRNA-treated neurons (siControl), as revealed by an anti-GFP (Flag) antibody; transfection of neurons with an siPFKFB3 efficiently reduced PFKFB3 protein and prevented glutamate-induced PFKFB3 accumulation. (**b**) Incubation of neurons with glutamate (100 *μ*M/15 min) increased, after 6 h, the rate of glycolysis, as assessed by the determination of \[3-^3^H\]glucose incorporation into ^3^H~2~O; this effect was abolished by preventing PFKFB3 accumulation in neurons previously transfected with siPFKFB3. (**c**) Glutamate treatment decreased, after 6 h, the rate of the PPP, as assessed by the determination of the difference between ^14^CO~2~ produced by \[1-^14^C\]glucose and that of \[6-^14^C\]glucose; this effect was abolished by siPFKFB3. (**d**) Glutamate treatment did not change GSx (left panel), but it increased GSSG (middle panel) and the oxidized glutathione redox status (GSSG/GSx; right panel); these effects were partially prevented by siPFKFB3. ^\*^*P*\<0.05 *versus* none; ^\#^*P*\<0.05 *versus* the corresponding siControl (ANOVA)](cdd201233f3){#fig3}

![NMDAR activation triggers oxidative stress and apoptotic death by switching PPP to glycolysis. (**a**) Transfection of neurons with an siRNA against PGI (siPGI), efficiently knocked down PGI protein abundance (left panel). Transfection of neurons with the full-length DNA encoding G6PD efficiently increased G6PD protein abundance (right panel). (**b**) Glutamate treatment (100 *μ*M/15 min) increased ROS in neurons, as assessed by MitoSox fluorescence by flow cytometry; this effect was prevented by knocking down PGI (siPGI) or PFKFB3 (siPFKFB3), overexpressing G6PD, or blocking NMDAR with MK801 (10 *μ*M). (**c**) Glutamate treatment increased apoptotic neuronal death, as assessed by annexin V^+^/7-AAD^−^ fluorescence by flow cytometry; this effect was prevented by silencing PGI (siPGI) or PFKFB3 (siPFKFB3), overexpressing G6PD or blocking NMDAR with MK801. ^\*^*P*\<0.05 *versus* none; ^\#^*P*\<0.05 *versus* siControl (glutamate; 5 × 10^4^ events were acquired in triplicate; results mean±S.E.M. from three independent neuronal preparations, *n*=3; ANOVA)](cdd201233f4){#fig4}

![Expression of APC^Cdh1^-insensitive PFKFB3 mimics glutamate at causing oxidative stress and neuronal death. (**a**) Glutamate treatment (100 *μ*M/15 min) increased ROS in neurons transfected with low levels of wild-type PFKFB3 cDNA; transfection of neurons with identical cDNA amounts of the KEN box-mut-PFKFB3 increased ROS to similar levels to those triggered by glutamate; glutamate did not further enhance ROS in neurons expressing mut-PFKFB3. (**b**) Glutamate increased apoptotic death of neurons transfected with low levels of PFKFB3 cDNA; transfection of neurons with identical cDNA amounts of mut-PFKFB3 increased apoptotic death to similar levels to those triggered by glutamate; glutamate did not further enhance apoptotic death in neurons expressing mut-PFKFB3. ^\*^*P*\<0.05 *versus* none (PFKFB3; 3 × 10^4^ events were acquired in triplicate; results mean±S.E.M. from three independent neuronal preparations, *n*=3; ANOVA)](cdd201233f5){#fig5}
